Biogen Idec’s “Outperform” Rating Reaffirmed at Credit Suisse (BIIB)
Other equities research analysts have also recently issued reports about the stock. Analysts at TheStreet reiterated a “buy” rating on shares of Biogen Idec in a research note to investors on Tuesday. Finally, analysts at Morgan Stanley raised their price target on shares of Biogen Idec from $170.00 to $177.00 in a research note to investors on Monday, March 11th.
Eleven analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $170.32.
Shares of Biogen Idec (NASDAQ: BIIB) traded down 0.63% during mid-day trading on Thursday, hitting $176.975. Biogen Idec has a one year low of $118.52 and a one year high of $178.41. The stock’s 50-day moving average is currently $166.6. The company has a market cap of $41.821 billion and a P/E ratio of 30.92.
Biogen Idec (NASDAQ: BIIB) last posted its quarterly earnings results on Monday, January 28th. The company reported $1.40 EPS for the quarter, missing the Thomson Reuters consensus estimate of $1.46 by $0.06. The company had revenue of $1.40 billion for the quarter, compared to the consensus estimate of $1.38 billion. During the same quarter last year, the company posted $1.51 earnings per share. Biogen Idec’s revenue was up 6.9% compared to the same quarter last year. Biogen Idec has set its FY13 guidance at $7.15-7.25 EPS. Analysts expect that Biogen Idec will post $7.72 EPS for the current fiscal year.
Biogen Idec Inc. (NASDAQ: BIIB) is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.